Revance Therapeutics, Inc.
DelistedCIK 1479290fmd_0X1RRQ7H8N7F9GZE3D44E3HETDManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2002 to Sep 30, 2024, 58 periods
| Line item | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | 0 | 0 | 0 | 4 | 0 | 15 | 78 | 133 | 234 |
| Research and development | 33 | 48 | 50 | 80 | 93 | 103 | 126 | 116 | 101 | 79 |
| Selling, general and administrative | 19 | 25 | 29 | 37 | 54 | 62 | 152 | 199 | 224 | 298 |
| Total operating expenses | 52 | 73 | 89 | 121 | 146 | 165 | – | – | – | – |
| Operating income | (52) | (72) | (88) | (120) | (143) | (164) | (273) | (275) | (342) | (317) |
| Interest expense | 11 | 1 | 1 | 0 | 0 | 0 | 15 | 6 | 16 | 19 |
| Other non-operating income (expense) | (0) | (0) | (1) | (1) | (1) | (0) | (1) | (1) | (2) | (1) |
| Income before taxes | – | (73) | (89) | (121) | (140) | (159) | – | – | – | – |
| Income tax expense | – | – | 0 | 0 | 3 | 0 | (3) | 0 | 1 | 0 |
| Net income from continuing operations | – | – | (89) | (121) | (143) | (159) | – | – | – | – |
| Net income | (63) | (73) | (89) | (121) | (143) | (159) | (282) | (281) | (356) | (324) |
| Net income to common shareholders | (63) | (73) | – | – | – | (159) | (282) | (281) | (356) | (324) |